An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS. Nevertheless, all approved drugs present clinical shortcomings, and opportunity lingers for a DMT that can present an even more-favorable balance of potent and low risk. Meanwhile, the development of neuroprotective and remyelinating strategies remains a critical goal. This Unmet Need content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the treatment of RR-MS, and the current level of unmet need in this area. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.

Table of contents

  • Multiple Sclerosis - Unmet Need - Detailed, Expanded Analysis Relapsing Remitting Multiple Sclerosis
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in RR-MS
        • Importance of Efficacy Attributes to Prescribing Decisions in RR-MS: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in RR-MS: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in RR-MS: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in RR-MS: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in RR-MS: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in RR-MS: Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in RR-MS: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in RR-MS: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Relapsing-Remitting Multiple Sclerosis
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for RR-MS: United States
        • Overall Performance of Key Therapies for RR-MS: Europe
        • Relative Performance of Key Therapies for RR-MS Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for RR-MS Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for RR-MS Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for RR-MS Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for RR-MS Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for RR-MS Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Neurologists’ Satisfaction with the Performance of Key Therapies for RR-MS on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors: United States
        • Surveyed Neurologists' Satisfaction with the Performance of Key Therapies for RR-MS on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors: Europe
      • Physician Rating of Unmet Need in Relapsing-Remitting Multiple Sclerosis
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in RR-MS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in RR-MS: Europe
        • Surveyed Neurologists’ Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in RR-MS: United States
        • Surveyed Neurologists’ Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in RR-MS: Europe
        • Surveyed Neurologists’ Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in RR-MS: United States
        • Surveyed Neurologists’ Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in RR-MS: Europe
      • Unmet Need in Relapsing-Remitting Multiple Sclerosis and Related Indications
        • Surveyed Neurologists’ Ascribed Level of Unmet Need in RR-MS and Related Indications: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need in RR-MS and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the RR-MS Market and Emerging Therapy Insights
        • Opportunity: A Novel DMT That Offers a Potent Efficacy with a More-Favorable Safety Profile
        • Opportunity: A Novel Therapy That Delivers a Greater Effect on Disability Progression
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • RR-MS Target Product Profile: Attribute Importance
        • RR-MS Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • RR-MS Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • RR-MS Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • RR-MS Market Simulations: Target Product Profiles Included in Scenario 1
        • RR-MS Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • RR-MS Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • RR-MS Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Tamara Blutstein, PhD; Dr. Ankuri Setia, BDS, PGDHM

Tamara Blutstein is a Senior Business Insights Analyst on the Central Nervous System, Pain, and Ophthalmology team. She is responsible for analyzing and forecasting pharmaceutical markets, primarily in Neurology indications, with specific expertise in Alzheimer’s disease, Parkinson’s disease, and ischemic stroke.

Prior to joining the company, Tamara was a postdoctoral fellow at Tufts University School of Medicine, where she studied the role of gliotransmission in the regulation of sleep and sleep homeostasis. She earned a Ph.D. in neuroscience from the University of Maryland School of Medicine where she conducted research on the role of gonadal hormones in modulating neuronal-glial communication. She holds a B.A. in neuroscience from Drew University.

Dr. Ankuri Setia is a Biopharma Insight Analyst in the CNS team at Decision Resources Group.

She comes with a work experience of 2 years as Knowledge Management Associate with practice across multiple therapy areas and indications on various functions in secondary research, competitive intelligence and product profiling, market assessment and pipeline analysis, and clinical trials assessment. She earned a Master of Healthcare Management degree from Institute of Health Management Research, a Deemed University.


Related Reports

Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

View Details

Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

View Details